SC 13G/A - TC BioPharm (Holdings) plc (0001872812) (Subject)
SC 13G/A - TC BioPharm (Holdings) plc (0001872812) (Subject)
SC 13G - TC BioPharm (Holdings) plc (0001872812) (Subject)
The Company's lead therapeutic will be available through a newly opened compassionate use programEDINBURGH, Scotland, May 15, 2024 /PRNewswire/ -- TC BioPharm (Holdings) PLC ("TC BioPharm" or the "Company") (NASDAQ:TCBP) a clinical stage biotechnology company developing platform allogeneic gamma-delta T cell therapies for cancer and other indications, today announced that the company's lead therapeutic TCB008 will be available to patients via a newly launched compassionate use program in the UK.
Shares of Zeta Global Holdings Corp. (NASDAQ:ZETA) rose sharply in today's pre-market trading after the company reported better-than-expected first-quarter financial results and increased its second-quarter revenue guidance. Zeta Global posted GAAP loss of 23 cents per share, compared to market expectations for a loss of 25 cents per share. The company's quarterly sales came in at $194.947 million topping estimates of $187.112 million, according to data from Benzinga Pro. Zeta Global shares jumped 15.3% to $15.00 in pre-market trading. Here are some other stocks moving in pre-market trading. Gainers reAlpha Tech Corp (NASDAQ:AIRE) gained 65.8% to $1.42 in pre-market trading a
6-K - TC BioPharm (Holdings) plc (0001872812) (Filer)
424B4 - TC BioPharm (Holdings) plc (0001872812) (Filer)
EFFECT - TC BioPharm (Holdings) plc (0001872812) (Filer)
No TCB008-related Adverse Events seen in any of the re-start patients6 Patients received second dose, 3 Patients received third dose, 1 Patient received fourth doseEDINBURGH, Scotland, Sept. 12, 2024 /PRNewswire/ -- TC BioPharm (Holdings) PLC ("TC BioPharm" or the "Company") (NASDAQ:TCBP) a clinical stage biotechnology company developing platform allogeneic gamma-delta T cell therapies for cancer and other indications, today announces the first patient has completed the full dose regimen in the ACHIEVE Phase 2b trial ongoing in the UK with no drug related Adverse Events seen in any of the re start patients. As previously stated, patients are eligible to receive up to 4 total doses of TCB und
EDINBURGH, Scotland, Sept. 9, 2024 /PRNewswire/ -- TC BioPharm (Holdings) PLC ("TC BioPharm" or the "Company") (NASDAQ:TCBP) a clinical stage biotechnology company developing platform allogeneic gamma-delta T cell therapies for cancer and other indications, today announced that it intends to begin Proof of Concept preclinical studies for its lead therapeutic TCB 008, for treatment in monkey pox. TCB008 is an allogeneic unmodified cell therapy that is made up of activated and expanded gamma delta T (GDT) cells which the company expects will have applications in treating the gl
EDINBURGH, Scotland, Sept. 6, 2024 /PRNewswire/ -- TC BioPharm (Holdings) PLC ("TC BioPharm" or the "Company") (NASDAQ:TCBP) a clinical stage biotechnology company developing platform allogeneic gamma-delta T cell therapies for cancer and other indications, today announced that it intends to begin Proof of Concept preclinical studies for its lead therapeutic TCB 008, for treatment in monkey pox. TCB008 is an allogeneic unmodified cell therapy that is made up of activated and expanded gamma delta T (GDT) cells which the company expects will have applications in treating the glo
EDINBURGH, Scotland, Feb. 23, 2023 /PRNewswire/ -- TC BioPharm (Holdings) PLC ("TC BioPharm" or the "Company") (NASDAQ:TCBP) a clinical stage biotechnology company developing platform allogeneic gamma-delta T cell therapies for cancer, today announced the appointment of Dr. Michael Leek to the position of Chief Technology Officer. Dr. Leek resumes operational duties as CTO after stepping down as executive chairman of the board. With more than 35 years experience in cell-based research and development, Co-founder, Michael Leek, Ph.D., had previously served as TC BioPharm's Exec
EDINBURGH, Scotland, Feb. 14, 2023 /PRNewswire/ -- TC Biopharm (Holdings) PLC ("TC Biopharm" or the "Company") (NASDAQ:TCBP) (NASDAQ:TCBPW), a clinical stage biotechnology company developing platform allogeneic gamma-delta T cell therapies for cancer, today announced the appointment of Arlene M. Morris to the position of Chair of the Board. Ms. Morris has held a seat on the TC BioPharm board as an independent director since 2022. An accomplished biotech executive and board member, with many years of experience, Ms. Morris has a proven track record of evolving businesses and en
Will oversee expansion of U.S. FDA Clinical TrialsEDINBURGH, Scotland, Jan. 30, 2023 /PRNewswire/ -- TC BioPharm (Holdings) PLC ("TC BioPharm" or the "Company") (NASDAQ:TCBP) (NASDAQ:TCBPW), a clinical stage biotechnology company developing platform allogeneic gamma-delta T cell therapies for cancer, today announced the appointment of Bree Harlin as Chief Clinical Officer (CCO), effective immediately. Ms. Harlin brings more than twenty years of experience in research, oncology and clinical stage drug development to TC BioPharm. Most recently she was with Loxo at Lilly, where
EDINBURGH, Scotland, Feb. 27, 2024 /PRNewswire/ -- TC BioPharm (Holdings) PLC ("TC BioPharm" or the "Company") (NASDAQ:TCBP) a clinical stage biotechnology company developing platform allogeneic gamma-delta T cell therapies for cancer and other indications, today announced that the company will host a shareholder update call on Tuesday, March 5th, 2024, at 10:00 am EST. Management intends to provide a brief update on the Company's operations, clinical trials as well as insight on the company's 2024 outlook and discuss business development efforts. The Company intends to provid
Conference Call to be held on Tuesday, February 21st, 2023 at Noon ET EDINBURGH, Scotland, Feb. 13, 2023 /PRNewswire/ -- TC BioPharm (Holdings) PLC ("TC BioPharm" or the "Company") (NASDAQ:TCBP) (NASDAQ:TCBPW), a clinical stage biotechnology company developing platform allogeneic gamma-delta T cell therapies for cancer, today announced that it now plans to host its shareholder update call on Tuesday, February 21, 2023, at 12:00 p.m. ET. The call was originally scheduled for Monday, February 20, 2023, at 10:00 a.m. ET. Management intends to provide a comprehensive update on th
Conference Call to be held on Monday, February 20th, 2023 at 10:00 am ET EDINBURGH, Scotland, Jan. 20, 2023 /PRNewswire/ -- TC BioPharm (Holdings) PLC ("TC BioPharm" or the "Company") (NASDAQ:TCBP) (NASDAQ:TCBPW), a clinical stage biotechnology company developing platform allogeneic gamma-delta T cell therapies for cancer, today announced the company will host a shareholder update call on Monday, February 20th, 2023, at 10:00 am EST. Management intends to provide a comprehensive update on the Company's clinical trial plan for its allogeneic gamma delta therapeutic in oncology
4 - TC BioPharm (Holdings) plc (0001872812) (Issuer)
4/A - TC BioPharm (Holdings) plc (0001872812) (Issuer)
4/A - TC BioPharm (Holdings) plc (0001872812) (Issuer)